ActivePhase 2Phase 3ACTRN12605000633684

Trial of an experimental soft contact lens designed to inhibit the progression of axial myopia in children.

Trial of an experimental frequent-replacement soft contact lens designed to correct vision and simultaneously produce myopic retinal defocus during distance and near vision in order to inhibit axial elongation of the eye and myopia progression in children.


Sponsor

Dr John Phillips, Senior Lecturer, Department of Optometry, University of Auckland

Enrollment

40 participants

Start Date

Nov 1, 2005

Study Type

Interventional

Conditions


Eligibility

Sex: Both males and femalesMin Age: 11 YearssMax Age: 14 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests a special soft contact lens designed to slow the progression of myopia (nearsightedness). It is looking for adults aged 11 to 14 who have been diagnosed with myopia. Participants would wear the experimental lens and have regular eye exams to track changes in their vision.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

A frequent replacement soft contact lens that both corrects vision and simultaneously produces myopic retinal defocus will be worn monocularly for 10 months by children with progressing myopia. The fe

A frequent replacement soft contact lens that both corrects vision and simultaneously produces myopic retinal defocus will be worn monocularly for 10 months by children with progressing myopia. The fellow eye will be corrected with a standard single vision frequent replacement soft contact lens. At cross-over (after 10 months) the identity of the eyes wearing the experimental and the single vision lenses will be reversed and the lenses will be worn for a further 10 months.


Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000633684